Oxford Biomedica plc provided revenue guidance for the year 2022. For the year, the company expects total revenues to be lower than in 2021 (but significantly ahead of 2020) due to a pause in vaccine manufacturing activity while discussions with AstraZeneca continue on a potential extension of the supply agreement.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
324.8 GBX | -1.89% | +3.02% | +47.50% |
May. 09 | Avon Protection wins UK MoD supply deal; Molten Ventures up | AN |
May. 09 | Molten Ventures wins UK MoD supply contract | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+47.50% | 419M | |
+8.29% | 114B | |
+10.21% | 104B | |
-11.90% | 22.41B | |
+0.64% | 22.28B | |
-5.52% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- OXB Stock
- News Oxford Biomedica plc
- Oxford Biomedica plc Provides Revenue Guidance for the Year 2022